Introduction
============

Mycoplasmas cause a wide variety of human disease, such as asthma, bronchiectasis, and pelvic inflammatory diseases ([@B59]). Several species of mycoplasma such as *Mycoplasma pneumoniae* in the respiratory tract, *M. genitalium* in the genitourinary tract cause human disease ([@B59]). Mycoplasma infections can place a big burden on healthcare systems, with more than 100,000 annual hospitalizations arising from *M. pneumoniae* in the US alone ([@B6]). In addition, mycoplasma infections of the respiratory and urogenital tract can be chronic. A better understanding of the pathogenesis of mycoplasma infections will contribute to vaccine development and treatment.

A key characteristic of the pathogenesis of chronic mycoplasma infections is the cross-talk between mycoplasmas and the host immune system ([@B6]). An inflammation response induced by the host's immunity is one of the main characteristics of *M. pneumoniae* infection and contributes to clinical presentations. Elucidating the mycoplasma cellular components will help us understand how the relatively small, and biochemically simple, mycoplasmas are capable of eliciting strong and chronic immune responses ([@B37]). Mycoplasmas can induce proinflammatory response through secreted toxins, surface antigens and other unclear mechanisms ([@B99]). Considering that Mycoplasma lack cell walls, cell wall proteins do not interacting with the host's immune system ([@B67]). Analysis of the mycoplasmal cell membrane demonstrated that several lipoprotein surface antigens elicit strong immune responses ([@B62]) through a distinct pathway than that seen with lipopolysaccharides ([@B69]). Unlike numerous other bacterial species, a large portion of mycoplasmal genome (6.68%) is dedicated to encoding various lipoproteins ([@B23]; [@B34]). The functionality of these genes is unknown, but they may drive adhesion and/or the initial stages of mycoplasmal infection since their products are cell surface proteins. Certain mycoplasmal lipoproteins have exonuclease activity that may be involved in the function of the ATP-binding cassette (ABC) transport system to import nucleic acid precursors ([@B77]). Little is known about the transcriptional regulation that occurs within these genes, especially since the mycoplasmal genome lacks many of the transcriptional regulators found in other bacteria ([@B37]; [@B23]).

The lipoylation mechanism of lipoproteins in mycoplasmas is similar to that of other bacteria ([@B72]). Bacterial lipoproteins play a major role in the cross-talk between bacteria and host immune responses. Bacterial lipoproteins contain a lipoylated amino-terminal cysteinyl residue that is usually *N*-acylated ([@B13]). However, an *N*-acyltransferase gene has not been found in *M. pneumoniae* or *M. genitalium* genome ([@B37]) and many mycoplasmal lipoproteins are not *N*-acylated \[such as lipoproteins from *M. gallisepticum* ([@B45]; [@B62])\]. Triacylation or diacylation of lipoproteins affects their recognition from different Toll like receptors ([@B46]). Thus, the unique structure of mycoplasmal lipoproteins can determine their immunomodulatory properties. Mycoplasma lipoproteins are all known to induce expression of proinflammatory cytokines including IL-1β, IL-6, and IL-2 ([@B28]; [@B38]). Several lipoproteins have been identified in mycoplasmas (**Table [1](#T1){ref-type="table"}**).

###### 

Major lipoproteins in mycoplasma species (isolated in humans).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lipoprotein/Gene ID                      Species of Mycoplasma                                       Original function          Immunomodulatory effect                                                                                                                                              References
  ---------------------------------------- ----------------------------------------------------------- -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------
  MPN052, MPN162, MPN415, MPN602, MPN611   *M. pneumoniae*                                             F~0~F~1~ ATP\              NF-kB activation, Pro-inflammatory diacylated lipoprotein                                                                                                            [@B82], [@B83]
                                                                                                       Synthase\                                                                                                                                                                                       
                                                                                                       subunit b                                                                                                                                                                                       

  MPN597                                   *M. pneumoniae*                                             F~0~F~1~ ATP\              Induction of inflammation, activation of the autophagy/TLR4-mediated pathway                                                                                         [@B83]; [@B80]
                                                                                                       Synthase\                                                                                                                                                                                       
                                                                                                       subunit 𝜀                                                                                                                                                                                       

  MPN611 MPN162 MG-142 MG-149              *M. pneumoniae M. pneumoniae M. genitalium M. genitalium*                              Activate NF-κB through TLR pathways                                                                                                                                  [@B81]

  MPN372                                   *M. pneumoniae*                                             ADP-ribosylating toxin,\   Induces extensive vacuolization and ultimate cell death of mammalian cells, facilitates adhesion to human surfactant protein A (hSP-A), activation of inflammasome   [@B51]; [@B49]
                                                                                                       CARDS toxin                                                                                                                                                                                     

  MPN333                                   *M. pneumoniae*                                             ABC Transporter            Activation of the autophagy/TLR4-mediated pathway                                                                                                                    [@B80]

  MPN142, MPN447, MPN453 Lp44              *M. pneumoniae M. salivarium*                               Cytadherence               Activation of inflammasome                                                                                                                                           [@B79], p. 2; [@B89]; [@B86]; [@B7]; [@B93]

  MPN141                                   *M. pneumoniae*                                             Cytadherence,\             Induction of pro-inflammatory cytokine production                                                                                                                    [@B89]; [@B50]
                                                                                                       P1 adhesin                                                                                                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Although Mycoplasma lipoproteins may function as immune-activators within their host, they also regulate mycoplasma colonization and translocation across mucosal membranes and facilitate host immune evasion ([@B20]; [@B16]). Understanding lipoprotein-induced immunomodulation will aid in developing novel treatments against Mycoplasmas ([@B57]). Herein, we review the evidence on the effects of mycoplasmal lipoproteins on host immunity (**Figure [1](#F1){ref-type="fig"}**). Given the complex immunomodulatory effects of mycoplasma lipoproteins we will dissect these effects by specific cell type (epithelial cells, neutrophils, myeloid cells, lymphocytes).

![Mechanisms of actions of mycoplasmal lipoproteins: Mycoplasmal lipoproteins lead to inflammatory responses and immune system activation through direct effects on both epithelial and immune cells. Initial adhesion to epithelia of respiratory tract is mediated through adhesins such as P1 (MPN141) as well as other accessory proteins. Epithelial cell activation as well as mycoplasmal lipoproteins induce secretion of chemokines such as IL-8 that promote neutrophilic infiltration and activation of neutrophils (through several mechanisms including NETosis). Neutrophilic activation is followed by activation of myeloid cells (monocytes, macrophages, dendritic cells) that ultimately leads to activation of adaptive immunity (lymphocytes). A key family of receptors that play an important role in recognizing, and inducing responses to Mycoplasmal lipoproteins are the Toll-Like Receptors (TLRs such as TLR2 and TLR6) that are key players in inflammatory responses upon infection. Mycoplasmal lipoproteins can also activate cells through the inflammasome and the pre-cursors of proinflammatory cytokines, such as IL-1β and IL-18, can be cleaved and activated in a caspase-dependent manner prior to their release. Non-TLR or inflammasome dependent mechanisms by which Mycoplasmal lipoproteins can lead to inflammatory responses and immune activation also exist (such as autophagy). TLRs (such as TLR-2 and TLR-6), also play an important role in inducing apoptosis in both monocyte and lymphocyte cell lines through induction of p38 MAPK, the apoptosis signal-regulating kinase (ASK1), caspase and the NF-kB pathways and the release of Nitric Oxide from macrophages. See text for further details. Given poorly understood mechanisms, further studies are needed to elucidate the mechanisms of immunomodulation mediated by mycoplasmal lipoproteins.](fmicb-09-01682-g001){#F1}

Effects of Mycoplasmal Lipoproteins on Epithelial Cells
-------------------------------------------------------

Epithelial cells are the main targets of *M. pneumoniae* and secrete cytokines in response to infections ([@B27]). Mycoplasmas directly induce *in vitro* production of chemotactic cytokines such as IL-8 by bronchial epithelial cells ([@B16]; [@B66]; [@B18]). Mycoplasmal lipoproteins may also have a major role in regulation of the cytokine response in respiratory epithelial cells during *M. pneumoniae* infection ([@B26]; [@B98]). Similar to the role of respiratory epithelial cells in eliciting a response during *M. pneumoniae* infection, epithelial cells lining the vagina and cervix may induce pro-inflammatory cytokines upon exposure to lipoproteins present in *M. genitalium* ([@B58]). However, the exact mechanisms that contribute to differential effects of mycoplasma lipoproteins on epithelial compared to immune cells remain unclear. Epithelial cells are also able to have an effect on Mycoplasmas. Upon contact with human epithelial cells *in-vivo, M. pneumoniae* can undergo transcriptional changes in lipoprotein related genes ([@B35]). Such an alteration in the genetic profile of the Mycoplasma upon coming into contact with epithelial cells represents the two-way dynamic existing between Mycoplasma and the host, where both parties are able to influence each other. Thus, the initial release of proinflammatory cytokines and chemokines by epithelial cells infected by Mycoplasmas can also induce early recruitment of immune cells such as neutrophils.

Effects of Mycoplasmal Lipoproteins on Neutrophils
--------------------------------------------------

Mycoplasma respiratory infections lead to the recruitment of polymorphonuclear leukocytes and subsequently monocytes/macrophages (M/M) and lymphocytes ([@B53]). The attraction of leukocytes to the site of infection is controlled by chemokines, which are chemotactic cytokines. The *M. pneumoniae*/IL-8/neutrophil axis likely plays a vital role in the pathogenesis of MPP and mycoplasmas directly induce *in vitro* production of chemotactic cytokines such as IL-8 by bronchial epithelial cells ([@B16]; [@B66]; [@B18]). An *M. fermentans* lipoprotein fraction induces secretion of IL-8 from cultured human M/M ([@B16]; [@B66]; [@B18]). The expression of such chemokines allows for the recruitment of leukocytes, such as neutrophils, to the site of infection, and it is this influx of leukocytes that comes to partially contribute to the inflammatory response seen upon mycoplasma infection ([@B94]).

Except for IL-8 and neutrophil chemotaxis, mycoplasma lipoproteins also induce NETosis. Neutrophil extracellular traps (NETs) are a major component of the first line of defense against invading pathogens and they involve a pathogen facilitated cell death by which neutrophils can extrude chromatin structures loaded with anti-microbial molecules to eliminate pathogens ([@B30]). Experiments using *M. agalactiae* have shown that mycoplasmas are capable of inducing NETosis upon infection, and mycoplasma lipoproteins are the component primarily responsible for activation of these pathways in neutrophils ([@B15]). Furthermore, it has also been shown that lipoproteins induce Toll-like Receptor 2 (TLR2) signaling that plays a pivotal role in neutrophil NETosis ([@B15]; [@B97]). Notably, NET formation ability decreases with patient age, and this may contribute to the susceptibility of older patients to mycoplasmal pathogens such as *M. pneumoniae* ([@B97]). More research is needed on the ability of lipoproteins to induce NETosis. Thus, mycoplasmal lipoproteins regulate neutrophilic host immune responses, which are the mainstay of pathogenesis of mycoplasmal infections. These early neutrophilic responses can also contribute to inflammatory responses from myeloid cells.

Effects of Mycoplasmal Lipoproteins on Myeloid Cells
----------------------------------------------------

Mycoplasmas induce activation of cytolytic activity of macrophages, and stimulation of cytokines (interleukin \[IL\]-1, IL-6, tumor necrosis factor-alpha \[TNF-α\]). Although several mycoplasmal proteins can induce these proinflammatory responses ([@B16]; [@B66]; [@B18]), mycoplasmal lipoproteins seem to be a major instigator of production of proinflammatory cytokines by myeloid cells such as M/M and dendritic cells ([@B22]; [@B36]). Non-denaturing detergents enriched with mycoplasmal lipoproteins, have modulatory capacities ([@B22]; [@B56]). Synthetic lipopeptides such as the Mycoplasma-derived lipopeptide MALP-2 from *M. fermentans* ([@B62]), FSL-1 (also known as Pam2C) from *M. salivarium* ([@B79]), and MPPL-1 from *M. pneumoniae* ([@B39]) were shown to have immunomodulatory properties. Activation of macrophages by mycoplasmal lipoproteins can occur at pico-molar concentrations of lipoproteins, making them extremely potent activators ([@B62]).

*In vitro* and *in vivo* studies demonstrated that the *M. fermentans*-derived membrane component MALP-2 (macrophage-activating lipopeptide 2) is the main active component that induces these proinflammatory responses ([@B52]). MALP-2 directly induced *in vitro* production of the proinflammatory cytokines TNF-α and IL-6 and the neutrophil-attracting CXC chemokines IL-8 and Growth-regulated Oncogene α (GRO-α) as well as the mononuclear leukocyte-attracting CC chemokines Monocyte chemoattractant protein-1 (MCP-1/CCL2), Macrophage inflammatory protein 1 alpha (MIP-1a/CCL3), and Macrophage inflammatory protein 1 beta (MIP-1b/CCL3) ([@B28]; [@B68]). The MALP-2 molecule is a potent activator of human monocytes.

Mycoplasmal lipoproteins in *M. hominis* such as lipoprotein MHO_4720 were recently shown to induce production of Interleukin-23 (IL-23), by dendritic cells through activation of inflammasome ([@B17]; [@B31]). Production of proinflammatory cytokines such as IL-23 has been shown to induce the expression of chemokines such as IL-17, allowing for effective containment of the infection ([@B94]). Additional *in vivo* studies have shown that many of the chemokines induced by mycoplasma infection in humans are conserved across species, such as macrophage inflammatory protein (MIP)-1β ([@B54]). Certain mycoplasmal lipoproteins, such as those from *M. hyopneumoniae* also elicit anti-inflammatory cytokines such as Interleukin-10 ([@B16]; [@B60]).

Inducing apoptosis of both monocytes and lymphocytes is a key step in allowing Mycoplasma to prolong their survival within their hosts, and has been documented in numerous Mycoplasma, with *M. bovis* being one of the most well-studied ([@B40]; [@B47]). Mycoplasma lipoproteins induce apoptosis in both monocyte (ex. HL-60, THP-1) and lymphocyte cell lines (ex. MOLT-4) ([@B2]; [@B41], [@B40]) and thus directly contribute to immune evasion.

Thus, mycoplasmal lipoproteins regulate myeloid based host immune responses and inflammatory responses, which are key mediators of pathogenesis of mycoplasmal infections. These innate immune responses may also drive responses from adaptive immunity (such as lymphocytic responses).

Effects of Mycoplasmal Lipoproteins on Lymphocytes
--------------------------------------------------

Mycoplasmas induce proliferation of T and B cells ([@B64]; [@B21]) through superantigens or unidentified factors. Various mycoplasmas also activate cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells ([@B91]) and induce expression of major histocompatibility antigens on B cells ([@B71]), IL-2 by T cells, interleukin (IL)-1 by macrophages ([@B63]) and interferons (IFNs) by lymphocytes ([@B3]). Collectively these mycoplasma-driven immunomodulatory effects contribute to the proliferation and maturation of both T and B lymphocytes as well as the activation of macrophages and NK cells ([@B4]).

During the early phases of infection, mycoplasmas usually induce an inflammatory and a humoral response preferentially directed against their membrane-bound, surface-exposed lipoproteins. Mycoplasmal lipoproteins such as spiralin induce T-cell-independent B-cell blastogenesis and secretion of proinflammatory cytokines ([@B14]). Lipoproteins from *M. fermentans* and *M. salivarium* induce TLR2- and caspase-mediated apoptosis in lymphocytes ([@B40]). The effects of mycoplasmal lipoproteins on lymphocytes may not be mediated by effects on TLR signaling on antigen presenting cells such as dendritic cells ([@B76]). Thus, mycoplasmal lipoproteins also regulate adaptive immune and function of both B cells and T cells.

Effects of Mycoplasmal Lipoproteins on Evasion of Host Immunity
---------------------------------------------------------------

Although lipoproteins have a major role as immune system activators, they also facilitate evasion of the host's immune response, leading to chronic mycoplasma infections ([@B9]; [@B32]). Mycoplasma lipoproteins facilitate immune evasion through several mechanisms such as creation of the mycoplasmal shield, lipoprotein antigenic variation, and protection from growth inhibiting host antibodies ([@B20]; [@B16]). Understanding the various modes of immune system evasion promises a better approach to treating mycoplasma infections.

Lipoproteins as the Basis for Mycoplasmal Shield Against Host Immune Defense Mechanisms
---------------------------------------------------------------------------------------

The ability of mycoplasma to encode numerous forms of lipoproteins that can potentially be expressed on their surface allows mycoplasmas to avoid host immune responses ([@B84]). Mycoplasmas are able to create a protective layer around themselves that can sterically hinder access of growth-inhibiting host antibodies and even macrophages ([@B20]; [@B84]). In addition to facilitating Mycoplasmal protection, the lipoprotein shield also plays an important role in hemadsorption and mycoplasmal adherence to surfaces ([@B11]; [@B96]). Mycoplasmas that are minimally shielded may be highly adherent while maximally shielded mycoplasmas are less adherent ([@B11]).

Variable Surface Antigen (Vsa) Lipoproteins as Facilitators of Immune Evasion
-----------------------------------------------------------------------------

In addition to the generation of a shield for protecting Mycoplasmas, lipoproteins are also able to protect Mycoplasma by undergoing variation. One major method by which lipoprotein variation in mycoplasmas can contribute to host immune evasion involves altering the length of these variable surface antigens (Vsa) ([@B96]). Mycoplasmas use antigenic variation not only to evade immune responses but also to adapt to each host ([@B10]). Vsa lipoproteins normally have a 242-amino acid N-terminus with a variable C-terminal domain that can contain up to 60 tandem repeating units which in themselves can range in size from 10 to 19 amino acids ([@B10]). Each cell can only transcribe one Vsa gene at a time, with silent Vsa genes missing the sequences necessary to make the conserved N-terminal domain ([@B78]). To achieve a large variety of Vsa recombination of lipoproteins, mycoplasmas use DNA recombination ([@B25]; [@B78]). Although a single cell may only transcribe a single Vsa gene, during an infection subpopulations of cells are able to express varying Vsa lipoproteins ([@B65]).

Despite the great importance Vsa size variation plays in facilitating prolonged mycoplasmal survival within hosts, adaptive immunity is still able to decrease mycoplasmal survival, thus necessitating phase variation of the shield as well ([@B85]). Thus, in addition to being able to conduct size variation of surface lipoproteins, mycoplasmas are also able to conduct phase (type) variation of their lipoproteins, hence the name Vsa lipoproteins ([@B25]; [@B16]). Phase variation *in vivo* is only seen upon the onset of an adaptive immune response, with no alterations occurring in Vsa expression if an organism lacks B and T cells ([@B33]). It is estimated that phase switching occurs at a frequency of around 10^-3^ per CFU per generation ([@B70]). In having the ability to undergo phase variation, mycoplasmas are able to evade host immune responses and indeed lead to chronic infections, similar to how Spirochetes might also use antigenic variation in order to establish a chronic infection ([@B16]; [@B19]). Thus, Mycoplasmal lipoproteins have pleotropic immunomodulatory effects and their mechanisms of actions need to be elucidated.

Mechanisms of Action of Mycoplasmal Lipoproteins
================================================

A key family of receptors that play an important role in recognizing, and inducing responses to Mycoplasmal lipoproteins are the Toll-Like Receptors (TLRs) that are key players in inflammatory responses upon infection ([@B1]; [@B90]). Two of the most well-studied TLRs are TLR2 and TLR6, both of which are pivotal in recognizing Mycoplasmal Macrophage-Activating Lipopeptide-2 (MALP-2), with the absence of either TLR leading to a lack of recognition and macrophage activation ([@B88]). Mycoplasmal lipoproteins can also activate myeloid cells through the inflammasome ([@B17]; [@B31]). Amongst the Mycoplasma capable of activating inflammasome with their lipoproteins are *M. salivarium* and *M. pneumoniae* ([@B80]; [@B87]). Through the activation of the inflammasome, the pre-cursors of proinflammatory cytokines, such as IL-1β and IL-18, can be cleaved and activated in a caspase-dependent manner prior to their release ([@B12]).

Non-pathogenic Mycoplasma also express lipoproteins, suggesting that a non-TLR dependent, or inflammasome dependent, mechanism exists by which Mycoplasmal lipoproteins can lead to immune activation ([@B80]). *M. pneumoniae* was still able to induce a strong inflammatory response in TLR2 KO mice ([@B83]). Introduction of known autophagy inhibitors to the TLR2 KO mice in turn lead to a significant fall in the inflammatory response, suggesting a role of autophagy in also leading to inflammatory responses ([@B83]).

Another mechanism by which Mycoplasmal lipoproteins are able to lead to immune system activation is through their initial adhesion to epithelia such as the respiratory tract in the case of *M. pneumoniae* ([@B48]). Such cytadherence is mediated through adhesins such as P1(MPN141) as well as other accessory proteins, and treatment of Mycoplasma with proteases or anti-P1 antibodies was seen to lead to a significant decrease in proinflammatory cytokine release ([@B98]; [@B38]). Cytadherence on behalf of *M. pneumoniae* was seen to generate a proinflammatory response through pathways involving both autophagy/TLR4 as well as inflammasome ([@B83]).

In addition to their roles as inductors of the inflammatory response, TLRs also play an important role in inducing apoptosis in both monocyte cell lines (ex. HL-60, HEK293, THP-1) and lymphocyte cell lines (ex. MOLT-4) upon binding of Mycoplasmal lipoproteins ([@B2]; [@B41]; [@B40]). The two main TLRs seen to play a role in this apoptotic pathway are TLR-2 and TLR-6, which through their activation allow induction of NF-kB ([@B2]; [@B95]) and the release of Nitric Oxide from macrophages ([@B61]; [@B40]). Mycoplasmal induced apoptosis seems to be mediated by activation of the p38 MAPK, the apoptosis signal-regulating kinase (ASK1) and the NF-kB pathways ([@B43]). Mycoplasmas such as *M. salivarium* and *M. fermentans* have also been seen to induce apoptosis through the more conventional caspase pathways ([@B41],[@B42]).

On the other hand, certain mycoplasmal lipoproteins, such as those seen in *M. fermentans*, can inhibit TNF-α mediated apoptosis ([@B29]). Thus, further research is needed to understand the pleotropic effects of mycoplasmal lipoproteins on apoptosis.

A better understanding of mechanisms of immunomodulation mediated by mycoplasmal lipoproteins may lead to therapies to attenuate the detrimental effects of mycoplasma infections.

Mycoplasmal Lipoproteins as Therapeutic Targets
===============================================

One of the most difficult parts of managing a Mycoplasmal infection is the inability to use many antibiotics such as beta-lactams ([@B8]). The development of drugs such as tigecycline that aim to reduce production of chemokines and lipoproteins through targeting of bacterial ribosomes is a growing discipline within the field of Mycoplasma research ([@B73]; [@B74]). Studies of tigecycline in a murine model have been able to confirm a significant drop of cytokine and chemokine production following infection with *M. pneumoniae* ([@B74]). Many studies that focus on development of a possible vaccine against Mycoplasma use inactivated Mycoplasma that can then be introduced to patients ([@B92]; [@B24]). [@B5] were able to show that inactivation of Mycoplasma using a photoactivatable alkylating agent (INA), with preservation of the surface lipoproteins, might be a possible mechanism by which Mycoplasma can be inactivated for vaccine development ([@B5]). Through a better understanding of bacterial lipoproteins and their interaction with the immune system, researchers are now aiming to develop vaccines that rely on the introduction of bacterial lipoproteins into patients to generate antibody responses ([@B55]). For example, the above has been achieved with the AvgC lipoprotein from *M. agalactiae* and shows promise for a vaccine against *M. agalactiae* infection ([@B75]). Such an approach to vaccine development is also currently being studied using bacterial lipoproteins, such as the OspA from Spirochetes ([@B44]; [@B100]). An innovative approach for treatment of Mycoplasmal infections would involve direct targeting of lipoproteins; however, such an approach remains to be established given the structure of mycoplasmal lipoproteins and their diverse immunomodulatory mechanisms. Importantly, the polypeptide Aspidasept^®^ which neutralizes endotoxin *in vivo* was previously shown to inhibit cytokines induced by the Mycoplasmal lipoproteins ([@B57]). Thus, a better understanding of Mycoplasmal lipoprotein epitopes, may promote progress in the field of antibodies, polypeptides or vaccines against Mycoplasma.

Conclusion
==========

Further studies are needed to promote understanding of the mechanisms of transcriptional regulation, phase variations and the numerous immunomodulatory effects (both acute and chronic) of Mycoplasmal lipoproteins. Given the decreasing efficacy of antibiotics against mycoplasmas, there is need for novel immunotherapies. Novel strategies such as use of inactivating agents that preserve the mycoplasmal surface lipoproteins, may advance vaccine development ([@B5]). Novel approaches such as use of polypeptides that attenuate proinflammatory effects of mycoplasmal lipoproteins need further investigation as novel therapeutic approaches for mycoplasmal infections ([@B57]). Ultimately, a better understanding of mycoplasmal lipoproteins can set the basis for the development of vaccines or antibodies against mycoplasmal lipoproteins and perhaps shed light on the pathogenesis of other vector based pathogens such as Spirochetes.
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